Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with
Biomea Fusion Inc (NASDAQ: BMEA) shares are trading higher. The company reported fourth-quarter results after the bell and announced an offering Wednesday morning. Several analysts are out with positive coverage.
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 90 points on Tuesday.
The Dow traded down 0.21% to 32,362.74 while the NASDAQ fell 0.77% to 11,678.39. The S&P 500, also fell, dropping, 0.37% to 3,962.87.
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 50 points on Tuesday.
The Dow traded up 0.16% to 32,484.24 while the NASDAQ fell 0.75% to 11,681.12. The S&P 500, also fell, dropping, 0.19% to 3,969.86.
Biomea Fusion Inc (NASDAQ: BMEA) shares are trading higher Tuesday after the company announced data from the initial cohorts of the ongoing Phase II study of BMF-219 in patients with
U.S. stocks traded mixed this morning, with the Nasdaq Composite dropping around 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.01% to 32,436.22 while the NASDAQ fell 0.52% to 11,707.41. The S&P 500, also fell, dropping, 0.21% to 3,969.06.